---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088335"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:58:03.888718+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q2 2023 DEXTENZA revenue $15M (+24% YoY), net loss $20.7M, $82.5M credit facility closed

## Summary
- DEXTENZA net product revenue $15.0M in Q2 2023, up 24% from $12.1M in Q2 2022 and 14% sequentially.
- Total net revenue $15.2M, up 24% YoY; net loss $(20.7)M or $(0.26) per share vs. $(18.8)M loss in Q2 2022.
- Closed $82.5M Barings credit facility; net cash proceeds ~$51.6M after repayment of MidCap debt; cash runway extended into 2025.
- First pivotal trial for OTX-TKI in wet AMD expected to initiate in Q3 2023; HELIOS Phase 1 NPDR trial enrollment completed.
- Full-year 2023 DEXTENZA revenue guidance expected to be upper end of $55M-$60M range; board added Dr. Adrienne Graves in July 2023.

## SEC filing metadata
- accession: 0001104659-23-088335
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465923088335/0001104659-23-088335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465923088335/tm2322873d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088335
- JSON: https://secwatch.observer/filing/0001104659-23-088335.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088335.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 7, 2023, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923088335/0001104659-23-088335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.